Swiss Noema Pharma raises CHF54m in Series A financing
Noema Pharma AG kicks off with CHF54m and licenced drug candidates from Roche AG.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.
Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 467 entries.
Entries by
Germany first EU country to launch COVID-19 therapy offensive?
1st December 2020 in News /by Thomas GabrielczykAfter months of lobbying by the BIOM biotech cluster, Bavaria is launching a 50m initiative to push the best and fastest COVID-19 therapies.
Moderna to file for EU approval of mRNA-1273 vaccine
30th November 2020 in News /by Thomas GabrielczykCOVID-19 mRNA vaccine developer Moderna Inc reported it will file for FDA and EMA authorisation of mRNA-1273 based on Phase III results.
Drug set to rescue COVID-19 patients at ICUs
26th November 2020 in News /by Thomas GabrielczykAviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients.
Polyphor AG bags funding for murepavadin
25th November 2020 in News /by Thomas GabrielczykPolyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.
EU COVID-19 antibody ready for clinical trials
18th November 2020 in News /by Thomas GabrielczykAs investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics candidate COR101 is set to enter clinical testing.
COVID-19: Moderna reports promising interim results
17th November 2020 in News /by Thomas GabrielczykAfter BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%.
BioNTech reports high efficacy of COVID-19 vaccine
10th November 2020 in News /by Thomas GabrielczykInterim data on BioNtechs/Pfizers COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA.
Vifor Pharma inks $340m deal with Angion Biomedica Inc.
9th November 2020 in News /by Thomas GabrielczykSwiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedicas experimental kidney drug ANG-3777.
Cell and gene therapy specialist Minaris expanding
3rd November 2020 in News /by Thomas GabrielczykJapanese CDMO Minaris Regenerative Medicine Co. Ltd will invest US$64.5m to expand its facilities in Europe and Asia.